378 related articles for article (PubMed ID: 24846793)
1. Bufalin loaded biotinylated chitosan nanoparticles: an efficient drug delivery system for targeted chemotherapy against breast carcinoma.
Tian X; Yin H; Zhang S; Luo Y; Xu K; Ma P; Sui C; Meng F; Liu Y; Jiang Y; Fang J
Eur J Pharm Biopharm; 2014 Aug; 87(3):445-53. PubMed ID: 24846793
[TBL] [Abstract][Full Text] [Related]
2. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity.
Yin P; Wang Y; Qiu Y; Hou L; Liu X; Qin J; Duan Y; Liu P; Qiu M; Li Q
Int J Nanomedicine; 2012; 7():3961-9. PubMed ID: 22888239
[TBL] [Abstract][Full Text] [Related]
3. Bufalin-loaded vitamin E succinate-grafted-chitosan oligosaccharide/RGD conjugated TPGS mixed micelles demonstrated improved antitumor activity against drug-resistant colon cancer.
Yuan Z; Yuan Y; Han L; Qiu Y; Huang X; Gao F; Fan G; Zhang Y; Tang X; He X; Xu K; Yin P
Int J Nanomedicine; 2018; 13():7533-7548. PubMed ID: 30532537
[TBL] [Abstract][Full Text] [Related]
4. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery.
Wang H; Wu J; Williams GR; Fan Q; Niu S; Wu J; Xie X; Zhu LM
J Nanobiotechnology; 2019 May; 17(1):60. PubMed ID: 31084622
[TBL] [Abstract][Full Text] [Related]
5. Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo.
Wu SH; Bau DT; Hsiao YT; Lu KW; Hsia TC; Lien JC; Ko YC; Hsu WH; Yang ST; Huang YP; Chung JG
Environ Toxicol; 2017 Apr; 32(4):1305-1317. PubMed ID: 27444971
[TBL] [Abstract][Full Text] [Related]
6. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
7. pH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells.
Vivek R; Nipun Babu V; Thangam R; Subramanian KS; Kannan S
Colloids Surf B Biointerfaces; 2013 Nov; 111():117-23. PubMed ID: 23787278
[TBL] [Abstract][Full Text] [Related]
8. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
9. Targeted poly (L-γ-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells.
Tavassolian F; Kamalinia G; Rouhani H; Amini M; Ostad SN; Khoshayand MR; Atyabi F; Tehrani MR; Dinarvand R
Int J Pharm; 2014 Jun; 467(1-2):123-38. PubMed ID: 24680951
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
11. Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model.
Zhuang YG; Xu B; Huang F; Wu JJ; Chen S
Pharmazie; 2012 Nov; 67(11):925-9. PubMed ID: 23210242
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
13. A novel drug "copper acetylacetonate" loaded in folic acid-tagged chitosan nanoparticle for efficient cancer cell targeting.
Pramanik A; Laha D; Pramanik P; Karmakar P
J Drug Target; 2014 Jan; 22(1):23-33. PubMed ID: 23987131
[TBL] [Abstract][Full Text] [Related]
14. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer.
Conte C; Ungaro F; Maglio G; Tirino P; Siracusano G; Sciortino MT; Leone N; Palma G; Barbieri A; Arra C; Mazzaglia A; Quaglia F
J Control Release; 2013 Apr; 167(1):40-52. PubMed ID: 23298613
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44.
Wang T; Hou J; Su C; Zhao L; Shi Y
J Nanobiotechnology; 2017 Jan; 15(1):7. PubMed ID: 28068992
[TBL] [Abstract][Full Text] [Related]
17. Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug.
Xia H; Gu G; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Song Q; Yao L; Tu Y; Chen H; Gao X; Chen J
Bioconjug Chem; 2013 Mar; 24(3):419-30. PubMed ID: 23350619
[TBL] [Abstract][Full Text] [Related]
18. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
Wang J; Tao X; Zhang Y; Wei D; Ren Y
Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
[TBL] [Abstract][Full Text] [Related]
19. Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways.
Li Y; Tian X; Liu X; Gong P
Carcinogenesis; 2018 May; 39(5):700-707. PubMed ID: 29546393
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells.
Roy K; Patel YS; Kanwar RK; Rajkhowa R; Wang X; Kanwar JR
Int J Nanomedicine; 2016; 11():25-44. PubMed ID: 26730188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
